Literature DB >> 19407243

Inactivation of the adenosine A2A receptor protects apolipoprotein E-deficient mice from atherosclerosis.

Huan Wang1, Weiyu Zhang, Chuhong Zhu, Christoph Bucher, Bruce R Blazar, Chunxiang Zhang, Jiang-Fan Chen, Joel Linden, Chaodong Wu, Yuqing Huo.   

Abstract

BACKGROUND: Atherosclerosis is a chronic inflammatory disease of the arterial vessel wall. The A(2A) receptor (A(2A)R) plays a central role in many antiinflammatory effects of adenosine. However, the role of A(2A)R in atherosclerosis is not clear. METHODS AND
RESULTS: The knockout of A(2A)R in apolipoprotein E-deficient (Apoe(-/-)/A(2A)R(-/-)) mice led to an increase in body weight and levels of blood cholesterol and proinflammatory cytokines, as well as the inflammation status of atherosclerotic lesions. Unexpectedly, Apoe(-/-)/A(2A)R(-/-) mice developed smaller lesions, as did chimeric Apoe(-/-) mice lacking A(2A)R in bone marrow-derived cells (BMDCs). The lesions of those mice exhibited a low density of foam cells and the homing ability of A(2A)R-deficient monocytes did not change. Increased foam cell apoptosis was detected in atherosclerotic lesions of Apoe(-/-)/A(2A)R(-/-) mice. In the absence of A(2A)R, macrophages incubated with oxidized LDL or in vivo-formed foam cells also exhibited increased apoptosis. A(2A)R deficiency in foam cells resulted in an increase in p38 mitogen-activated protein kinase (MAPK) activity. Inhibition of p38 phosphorylation abrogated the increased apoptosis of A(2A)R-deficient foam cells.
CONCLUSIONS: Inactivation of A(2A)R, especially in BMDCs, inhibits the formation of atherosclerotic leisons, suggesting that A(2A)R inactivation may be useful for the treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19407243      PMCID: PMC2724834          DOI: 10.1161/ATVBAHA.109.188839

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  37 in total

1.  Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo.

Authors:  Dmitriy Lukashev; Akio Ohta; Sergey Apasov; Jiang-Fan Chen; Michail Sitkovsky
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

2.  Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells.

Authors:  Yuan-Ji Day; Liping Huang; Marcia J McDuffie; Diane L Rosin; Hong Ye; Jiang-Fan Chen; Michael A Schwarzschild; J Stephen Fink; Joel Linden; Mark D Okusa
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

3.  Sensitivity to selective adenosine A1 and A2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices.

Authors:  Manuela Marcoli; Luca Raiteri; Andrea Bonfanti; Angela Monopoli; Ennio Ongini; Maurizio Raiteri; Guido Maura
Journal:  Neuropharmacology       Date:  2003-08       Impact factor: 5.250

4.  Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages.

Authors:  Allison B Reiss; Mohammad M Rahman; Edwin S L Chan; M Carmen Montesinos; Nahel W Awadallah; Bruce N Cronstein
Journal:  J Leukoc Biol       Date:  2004-06-14       Impact factor: 4.962

5.  Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice.

Authors:  Edwin Kanters; Manolis Pasparakis; Marion J J Gijbels; Monique N Vergouwe; Iris Partouns-Hendriks; Remond J A Fijneman; Björn E Clausen; Irmgard Förster; Mark M Kockx; Klaus Rajewsky; Georg Kraal; Marten H Hofker; Menno P J de Winther
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

Review 6.  Oxidized low density lipoprotein and innate immune receptors.

Authors:  Yury I Miller; Mi-Kyung Chang; Christoph J Binder; Peter X Shaw; Joseph L Witztum
Journal:  Curr Opin Lipidol       Date:  2003-10       Impact factor: 4.776

7.  Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage.

Authors:  J Stephen Fink; Anti Kalda; Hoon Ryu; Edward C Stack; Michael A Schwarzschild; Jiang-Fan Chen; Robert J Ferrante
Journal:  J Neurochem       Date:  2004-02       Impact factor: 5.372

Review 8.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis.

Authors:  Gail W Sullivan; Guodong Fang; Joel Linden; W Michael Scheld
Journal:  J Infect Dis       Date:  2004-04-28       Impact factor: 5.226

Review 10.  Adenosine: an endogenous regulator of innate immunity.

Authors:  György Haskó; Bruce N Cronstein
Journal:  Trends Immunol       Date:  2004-01       Impact factor: 16.687

View more
  28 in total

1.  A2b adenosine receptor regulates hyperlipidemia and atherosclerosis.

Authors:  Milka Koupenova; Hillary Johnston-Cox; Alexander Vezeridis; Haralambos Gavras; Dan Yang; Vassilis Zannis; Katya Ravid
Journal:  Circulation       Date:  2011-12-05       Impact factor: 29.690

2.  An Endocrine Genetic Signal Between Blood Cells and Vascular Smooth Muscle Cells: Role of MicroRNA-223 in Smooth Muscle Function and Atherogenesis.

Authors:  Zhen Shan; Shanshan Qin; Wen Li; Weibin Wu; Jian Yang; Maoping Chu; Xiaokun Li; Yuqing Huo; Gary L Schaer; Shenming Wang; Chunxiang Zhang
Journal:  J Am Coll Cardiol       Date:  2015-06-16       Impact factor: 24.094

Review 3.  Regulation of foam cells by adenosine.

Authors:  Allison B Reiss; Bruce N Cronstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

Review 4.  A2 adenosine receptors and vascular pathologies.

Authors:  Hillary A Johnston-Cox; Milka Koupenova; Katya Ravid
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

Review 5.  Regulation of macrophage function by adenosine.

Authors:  György Haskó; Pál Pacher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

Review 6.  Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines.

Authors:  Sven Nylander; Rainer Schulz
Journal:  Br J Pharmacol       Date:  2016-02-24       Impact factor: 8.739

7.  Adenosine and blood platelets.

Authors:  Hillary A Johnston-Cox; Katya Ravid
Journal:  Purinergic Signal       Date:  2011-02-08       Impact factor: 3.765

8.  CD73 Promotes Age-Dependent Accretion of Atherosclerosis.

Authors:  Nadia R Sutton; Diane Bouïs; Kris M Mann; Imran M Rashid; Alexandra L McCubbrey; Matt C Hyman; Daniel R Goldstein; Annie Mei; David J Pinsky
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-10-17       Impact factor: 8.311

9.  A₁ adenosine receptor deficiency or inhibition reduces atherosclerotic lesions in apolipoprotein E deficient mice.

Authors:  Bunyen Teng; Jonathan D Smith; Michael E Rosenfeld; Peggy Robinet; Mary E Davis; R Ray Morrison; S Jamal Mustafa
Journal:  Cardiovasc Res       Date:  2014-02-12       Impact factor: 10.787

10.  Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response.

Authors:  Yuqing Huo; Xin Guo; Honggui Li; Huan Wang; Weiyu Zhang; Ying Wang; Huaijun Zhou; Zhanguo Gao; Sucheta Telang; Jason Chesney; Y Eugene Chen; Jianping Ye; Robert S Chapkin; Chaodong Wu
Journal:  J Biol Chem       Date:  2009-11-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.